Pieris Pharmaceuticals (PIRS) Value Adjusted for Debt and Cash
Pieris Pharmaceuticals (PIRS) is developing innovative protein-based therapies to combat oncology and respiratory pathologies. The business relies on an anticalin platform, where key success factors include asthma test results and tranches from AstraZeneca. The price action based on the Enterprise Value metric is 1687.08. Currently, Stephen Yarrow is reorganizing the asset portfolio, seeking new allies following a series of unsuccessful experiments.
Pieris Pharmaceuticals (PIRS) - metric breakdowns and financial figures
Under crisis management at Pieris Pharmaceuticals (PIRS) following the termination of strategic partnerships, monitoring the total enterprise value becomes a critical tool for assessing the issuer's viability. By analyzing the company's valuation via the EV metric, an investor sees the sum of market capitalization and net debt, which determines the actual acquisition price of the asset, accounting for all liabilities and available liquidity.